Publicacións nas que colabora con Santos Castañeda Sanz (73)

2024

  1. Combined use of QRISK3 and SCORE2 increases identification of ankylosing spondylitis patients at high cardiovascular risk: Results from the CARMA Project cohort after 7.5 years of follow-up

    Seminars in Arthritis and Rheumatism, Vol. 66

  2. Leflunomide as a therapeutic alternative to methotrexate as a glucocorticoid-sparing agent in polymyalgia rheumatica

    Rheumatology Advances in Practice

  3. Lights and shadows on the efficacy of tocilizumab monotherapy in large vessel giant cell arteritis

    Rheumatology (Oxford, England), Vol. 63, Núm. 1, pp. 6-7

  4. Metabolic Syndrome: A Predisposing Factor for Rheumatoid Arthritis

    Journal of Rheumatology

  5. Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

    RMD open, Vol. 10, Núm. 2

2023

  1. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Challenges in the diagnosis of polymyalgia rheumatica and related giant cell arteritis

    Expert Review of Clinical Immunology, Vol. 19, Núm. 5, pp. 517-526

  3. Classifying extracranial large-vessel giant cell arteritis using the new 2022 American College of Rheumatology/EULAR classification criteria: comment on the article by Ponte et al

    Arthritis and Rheumatology

  4. Co-occurrence of giant cell arteritis in patients with polymyalgia rheumatica. Comment on the article by Nielsen AW, et al

    Seminars in Arthritis and Rheumatism

  5. Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 910-915

  6. Cranial and extracranial large-vessel giant cell arteritis share a genetic pattern of interferon-gamma pathway

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 864-869

  7. Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  8. Epidemiology and clinical domains of Behçet's disease in the Cantabria region, Northern Spain

    Clinical and experimental rheumatology, Vol. 41, Núm. 10, pp. 1991-1997

  9. Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?

    International Journal of Molecular Sciences, Vol. 24, Núm. 17

  10. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

  11. Polymyalgia rheumatica: when should we suspect an underlying large vessel vasculitis?

    Clinical and experimental rheumatology

  12. Positron Emission Computed Tomography Spectrum of Large Vessel Vasculitis in a Tertiary Center: Differences in 18F-fluorodeoxyglucose Uptake between Large Vessel Vasculitis with Predominant Cranial and Extracranial Giant Cell Arteritis Phenotypes

    Journal of Clinical Medicine, Vol. 12, Núm. 19

  13. Systemic treatment in sarcoidosis: Experience over two decades

    European Journal of Internal Medicine, Vol. 108, pp. 60-67

2022

  1. Baricitinib in severe and refractory peripheral ulcerative keratitis: a case report and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

  2. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

    Journal of Clinical Medicine, Vol. 11, Núm. 19